The next-generation heart pump to change patients’ lives and create a new standard of care

Description du projet

Une pompe implantable intelligente pour les insuffisances cardiaques avancées

L’insuffisance cardiaque est une maladie potentiellement mortelle entrainée par un cœur incapable de pomper suffisamment de sang pour répondre aux besoins du corps. Pour les patients atteints d’insuffisance cardiaque avancée et trop âgés ou fragiles pour accepter une transplantation cardiaque, les dispositifs d’assistance ventriculaire gauche implantables (DAVG) sont apparus comme une nouvelle option de traitement. Le projet Calypso, financé par l’UE, mettra sur le marché un DAVG révolutionnaire mis au point par la société française CORWAVE. Ce nouvel appareil s’appuie sur une technologie révolutionnaire unique et brevetée, la membrane ondulatoire. Contrairement aux appareils existants qui sont des pompes rotatives à débit continu, le DAVG de CorWave est une pompe intelligente qui produit un flux sanguin physiologique et pulsatile pour redonner aux patients une vie normale en minimisant les effets secondaires.

Objectif

Advanced heart failure (HF) is a deadly disease, with a booming incidence driven by durable socio-demographic trends. Left ventricular assist devices (LVADs) are a life-saving therapy for advanced HF patients and represent a billion-euro market. However, only 13% of the 60,000 eligible patients are implanted with current LVADs each year, due to the extremely high rate of severe adverse events (stroke, bleeding, infection) and the limited quality of life.
CorWave is an innovative French SME created in 2011 with a mission to create a new standard of care for advanced HF patients. The company is developing a game-changing LVAD, which relies on a unique and patented breakthrough technology, the wave membrane. Unlike all current devices, which are continuous-flow rotary pumps, CorWave LVAD is a smart pump producing a physiologic and pulsatile blood flow, to restore a normal life to patients with minimal side effects. CorWave LVAD will cut in half severe complications and rehospitalisation costs. CorWave projects to take over 60% of the market and reach up to €1.1 billion of turnover in 2030, by taking advantage of the LVAD market structure, which is very favourable to new entrants (concentrated on a few centres), and by increasing the penetration rate.
We have built a team of 50 experienced people, including world-class experts, and have gained a strong market traction. The clinical centres who support us through letters of intent are worth >25% of the European market. We partner with a network of industrial suppliers and have our own pilot production unit to manufacture prototypes that have proved successful in preclinical studies.
Thanks to EIC Accelerator, CorWave will transform a very promising preclinical prototype (TRL 6-7) into an industrial CE-marked medical device (TRL 8-9) that patients, clinicians and payers are waiting for. EIC Accelerator would place CorWave on a trajectory to become a global medtech leader with an outstanding socioeconomic impact on the EU.

Champ scientifique

Programme(s)

Thème(s)

EIC-SMEInst-2018-2020 - SME instrument

Appel à propositions

H2020-EIC-SMEInst-2018-2020

Voir d’autres projets de cet appel

Sous appel

H2020-EIC-SMEInst-2018-2020-3

Régime de financement

SME - SME instrument

Coordinateur

CORWAVE

Contribution nette de l'UE

€ 2 495 675,00

Adresse

19-23 ALLEE DE L'EUROPE
92110 CLICHY
France

PME

Oui

Région

Ile-de-France Ile-de-France Hauts-de-Seine

Type d’activité

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Liens

Contacter l’organisation

Participation aux programmes de R&I de l'UE

Réseau de collaboration HORIZON

Coût total

€ 3 565 250,00